Suppr超能文献

具有低、中、高前列腺特异性抗原速度的局限性前列腺癌男性患者特征的差异。

Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity.

机构信息

Arizona Cancer, Tucson, Arizona, USA.

出版信息

Intern Med J. 2012 Apr;42(4):374-80. doi: 10.1111/j.1445-5994.2011.02473.x.

Abstract

BACKGROUND

Current diagnostic tools are inadequate for reliable prediction of prostate cancer (PCa) aggressiveness in patients with localised disease. This results in many patients being exposed to potentially unnecessary invasive treatment and its associated morbidities. In order to develop appropriate treatment strategies, it is essential to understand the differences between patients who will develop aggressive disease and those who will not.

METHODS

A longitudinal study was conducted in men with localised PCa on active surveillance for their disease in which 140 subjects were followed every 3 months for up to 5 years. Change in prostate-specific antigen (PSA) over time (PSA velocity) was used as a marker for PCa progression. Subjects were categorised as slow, intermediate and fast progressors based on tertiles of PSA velocity. Differences in baseline markers were investigated using logistic regressions. Two approaches were used, slow progressors were compared with fast progressors (model 1) and slow progressors were compared with combination of intermediate and fast progressors (model 2).

RESULTS

Aspirin was negatively associated with high PSA velocity in model 1 (odds ratio (95% confidence interval): 0.24 (0.06, 0.94), P-value = 0.04) and model 2 (odds ratio = 0.22 (0.08, 0.59), P-value = 0.003), whereas smoking was positively associated with high PSA velocity in model 1 (1.03 (0.92, 1.13), P-value = 0.01).

CONCLUSIONS

These findings highlight the role of aspirin and smoking in PCa progression. They have potential towards risk stratification as well as PCa prevention and hence need to be investigated further.

摘要

背景

目前的诊断工具不足以可靠地预测局部前列腺癌(PCa)患者的侵袭性。这导致许多患者接受潜在的不必要的侵入性治疗及其相关的发病率。为了制定适当的治疗策略,了解哪些患者会发展为侵袭性疾病,哪些患者不会发展为侵袭性疾病至关重要。

方法

对接受主动监测的局部 PCa 男性进行了一项纵向研究,其中 140 名患者每 3 个月随访一次,最长随访 5 年。前列腺特异性抗原(PSA)随时间的变化(PSA 速度)被用作 PCa 进展的标志物。根据 PSA 速度的三分位数,将患者分为缓慢、中度和快速进展者。使用逻辑回归分析了基线标志物的差异。使用了两种方法,缓慢进展者与快速进展者进行比较(模型 1),以及缓慢进展者与中速和快速进展者的组合进行比较(模型 2)。

结果

在模型 1 中,阿司匹林与高 PSA 速度呈负相关(优势比(95%置信区间):0.24(0.06,0.94),P 值=0.04)和模型 2(优势比=0.22(0.08,0.59),P 值=0.003),而吸烟与高 PSA 速度呈正相关在模型 1 中(1.03(0.92,1.13),P 值=0.01)。

结论

这些发现强调了阿司匹林和吸烟在 PCa 进展中的作用。它们有可能用于风险分层以及 PCa 的预防,因此需要进一步研究。

相似文献

3
4
Association of obesity and smoking with PSA and PSA velocity in men with prostate cancer.
Am J Mens Health. 2011 May;5(3):272-8. doi: 10.1177/1557988310390030.
5
Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression.
Clin Genitourin Cancer. 2020 Apr;18(2):e174-e179. doi: 10.1016/j.clgc.2019.09.014. Epub 2019 Sep 26.
6
Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
Lancet Oncol. 2015 Dec;16(16):1667-76. doi: 10.1016/S1470-2045(15)00361-7. Epub 2015 Nov 10.
9
The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
Eur Urol. 2018 Aug;74(2):204-210. doi: 10.1016/j.eururo.2017.12.028. Epub 2018 Jan 10.

引用本文的文献

1
A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies.
Eur Urol. 2014 Dec;66(6):1054-64. doi: 10.1016/j.eururo.2014.08.059. Epub 2014 Sep 18.

本文引用的文献

1
Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer.
Cancer Prev Res (Phila). 2010 Aug;3(8):1035-43. doi: 10.1158/1940-6207.CAPR-09-0143. Epub 2010 Jul 20.
3
Active surveillance for early-stage prostate cancer: defining the triggers for intervention.
J Clin Oncol. 2010 Jun 10;28(17):2807-9. doi: 10.1200/JCO.2010.28.5817. Epub 2010 May 3.
4
Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity.
Prostate. 2010 Jun 1;70(8):883-8. doi: 10.1002/pros.21122.
5
Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.
J Clin Oncol. 2010 Jan 1;28(1):126-31. doi: 10.1200/JCO.2009.24.2180. Epub 2009 Nov 16.
6
Prostate cancer: the new evidence base for diagnosis and treatment.
Pathology. 2007 Dec;39(6):537-44. doi: 10.1080/00313020701684458.
7
Inflammation in the etiology of prostate cancer: an epidemiologic perspective.
Urol Oncol. 2007 May-Jun;25(3):242-9. doi: 10.1016/j.urolonc.2006.09.014.
8
A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence.
J Natl Cancer Inst. 2007 Apr 18;99(8):608-15. doi: 10.1093/jnci/djk132.
9
Overdiagnosis and overtreatment of early detected prostate cancer.
World J Urol. 2007 Mar;25(1):3-9. doi: 10.1007/s00345-007-0145-z. Epub 2007 Feb 14.
10
Circulating biomarkers for prostate cancer.
World J Urol. 2007 Apr;25(2):111-9. doi: 10.1007/s00345-007-0160-0. Epub 2007 Mar 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验